Benitec Biopharma Ltd

www.benitec.com

Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Medical

ASHER BIO PRESENTS NEW PRECLINICAL DATA AT ASH APPLYING CIS-TARGETED CYTOKINES TO ENHANCE CAR-T CELL THERAPIES

Asher Bio | December 13, 2022

news image

Asher Biotherapeutics, Inc. a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced new preclinical data demonstrating proof-of-concept for cis-targeted cytokines as a novel strategy for enhancing chimeric antigen receptor T cell engraftment, expansion, and functionality culminating in the delivery of improved anti-tumor activity. This data will be presented in a poster at the 64th American Society of Hematology Annual Me...

Read More

Cell and Gene Therapy

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

news image

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More

MedTech, Industrial Impact

ARGENX AND GENMAB ENTER PARTNERSHIP TO ADVANCE ANTIBODY THERAPIES IN IMMUNOLOGY AND ONCOLOGY

Globenewswire | April 18, 2023

news image

argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address ...

Read More

Cell and Gene Therapy

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene | June 28, 2022

news image

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1...

Read More
news image

Cell and Gene Therapy, Medical

ASHER BIO PRESENTS NEW PRECLINICAL DATA AT ASH APPLYING CIS-TARGETED CYTOKINES TO ENHANCE CAR-T CELL THERAPIES

Asher Bio | December 13, 2022

Asher Biotherapeutics, Inc. a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced new preclinical data demonstrating proof-of-concept for cis-targeted cytokines as a novel strategy for enhancing chimeric antigen receptor T cell engraftment, expansion, and functionality culminating in the delivery of improved anti-tumor activity. This data will be presented in a poster at the 64th American Society of Hematology Annual Me...

Read More
news image

Cell and Gene Therapy

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More
news image

MedTech, Industrial Impact

ARGENX AND GENMAB ENTER PARTNERSHIP TO ADVANCE ANTIBODY THERAPIES IN IMMUNOLOGY AND ONCOLOGY

Globenewswire | April 18, 2023

argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address ...

Read More
news image

Cell and Gene Therapy

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene | June 28, 2022

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us